I Am You See

I Am You See = IMUC

Email [e-mail] to be added to my free newsletter, I sent this out Friday morning:

Hey guys,

It will be a couple weeks before I am done writing, but I wanted to give you a heads up that I'm researching a stock for an in-depth article. The last three stocks I wrote about in depth are up about 100%:

seekingalpha.com/article/1456761-5-reaso...

seekingalpha.com/article/1254581-5-reaso...

seekingalpha.com/article/1106981-3-reaso...

This stock is Immunocellular Therapeutics (OTCPK:IMUC).

IMUC has an immunotherapy platform that targets cancer stem cells. They take dendritic cells from a patient with cancer and teach these cells to recognize cancer stem cell markers (antigens). They re-inject the dendritic cells back in the patient, and the DCs initiate a response from t-cells to go after the tumor stem cells. They are in trial for this in terminal brain cancer (glioblastoma multiforme), but the platform can be used for many other cancers and they are starting 2 more trials this year (one for ovarian cancer, another for recurrent glioblastoma). Their first glioblastoma study was just a small phase I study, but the results were extremely encouraging by cancer treatment standards -survival times nearly doubled, and 6 of 16 patients were still alive after 4 years. The current study is phase 2 but there is plenty of precedent that they could get approval from this trial if the results are good enough (because the disease is so fatal and there are no good treatments).

Here are the results from the phase I study:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3541928/#!po=20.8333

Here is a presentation from the company:

http://www.imuc.com/pdf/2012/other/IMUC%20MP.pdf

And here is some background on cancer stem cells:

http://docs.abcam.com/pdf/cancer/biology-cancer-stem-cells-poster.pdf

Interestingly, IMUC also just got removed from the Russell 2000 at the end of June (valuation reasons not business reasons) and the stock fell by about 25% since Russell first announced (anticipation of forced selling from Russell-tracking funds).

IMUC is currently valued a little over $100 million with a share price in the $2s, but the last 3 analyst price targets were $6, $6, and $18. A glioblastoma approval by itself should make for a $1 billion market cap, or about $18. But if the platform proves successful in other cancers, the upside is much higher.

Please do your due diligence on this if you like it, I like it but there are no guarantees.

Success to trade,

Joe

Disclosure: I am long OTCPK:IMUC.